CA-ARMIS
12.12.2023 14:01:40 CET | Business Wire | Press release
Armis, the asset intelligence cybersecurity company, today announced that it has been named a leader by analyst group Quadrant Knowledge Solutions in three 2023 SPARK Matrix™ reports for Q4 2023. The reports: SPARK Matrix™: Vulnerability Management, Q4 2023, SPARK Matrix™: Operational Technology (OT) Security, Q4 2023, and SPARK Matrix™: Connected Medical Device Security Solutions, Q4 2023, place three Armis Centrix™ solutions as a Technology Leader with significant customer impact in the areas of Vulnerability Management, Operational Technology Security and Connected Medical Device Security.
“Our Leader position in these three reports is a testament to our commitment to innovation and customer success, and helping organizations see, protect and manage their entire attack surface in real-time,” said Dana Gilboa, Chief Product Officer of Armis. “We are extremely proud that Armis is positioned as a Leader on both the Technology Leader axis and the Customer Impact axis for all three reports. We also want to extend a sincere thank you to the Armis customers who took the time to provide feedback on Armis to Quadrant Knowledge Solutions.”
The SPARK Matrix™ reports analyzed three of Armis’ four core solutions: Vulnerability Management, OT/IoT Security, and Medical Device Security, which are all built on Armis Centrix™, the Armis cyber exposure management platform. Powered by the Armis AI-driven Asset Intelligence Engine, Armis Centrix™ is a seamless, frictionless, cloud-based platform that proactively identifies all cyber asset risks, remediates vulnerabilities, blocks threats and protects the entire attack surface.
SPARK Matrix™ reports analyze the vendor landscape of a technology category and vendor product capabilities. Vendors are evaluated according to their product offerings, market share and customer satisfaction to help CIOs and CISOs make informed technology decisions.
When evaluating why Armis is a technology leader in each of these three core areas, Quadrant Knowledge Solutions shared in its reports:
- Vulnerability Management - “Armis Centrix™ for Vulnerability Prioritization and Remediation bridges critical coverage gaps unattended by Vulnerability assessment tools with aggregation of details such as ownership and location to create full visibility of the attack surface. Armis Centrix™ for Vulnerability Prioritization and Remediation provides holistic visibility into the user’s overall risk and attack surface. The platform also provides the business context of business-critical assets based on their roles. Armis Centrix™ Asset Vulnerability Prioritization and Remediation helps the organization reduce its attack surface by analyzing attributes of devices and overlaying threat intel as a part of the analysis.”
- Operational Technology Security - “Armis Centrix™ for OT/IoT security enables organizations to see and secure OT/IOT networks and physical assets, ensure uptime, and build an effective & comprehensive security strategy. It is powered by Armis’ AI-driven Asset Intelligence Engine and oversees, secures, protects, and manages a wide range of assets in real-time. The cloud-based platform proactively mitigates all cyber asset risks, remediates vulnerabilities, blocks threats, and protects the entire attack surface. Armis for OT/IoT security provides deep visibility to all OT assets as well as to the OT/ICS networks and environment. It allows companies to manage the OT/IT convergence, bridge the IT / OT gap and protect OT networks, monitor connectivity, and track behavior.”
- Connected Medical Device Security - “Armis Centrix™ for Medical Device Security offers features like real-time complete visibility into medical device inventory, information regarding device usage for increasing utilization efficiency, medical device risk assessment based on vulnerabilities, identifying Protected Health Information (PHI) breaches, identifying and remediating threats, and automating security of medical devices. The product is also equipped with an Asset Intelligence Engine with over 20 million device profiles, and the AI-powered Armis Standard Query.”
Learn more about each of these Quadrant Knowledge Solutions reports at the below links:
- SPARK Matrix™: Vulnerability Management, Q4 2023
- SPARK Matrix™: Operational Technology Security, Q4 2023
- SPARK Matrix™: Connected Medical Device Security, Q4 2023
To read our blog, please visit: https://www.armis.com/blog/armis-is-named-a-leader-in-three-2023-quadrant-spark-matrix-reports/
For additional analyst reports sharing insights about Armis Centrix™, go here: https://www.armis.com/resources/?type=analyst-reports
About Armis
Armis, the asset intelligence cybersecurity company, protects the entire attack surface and manages the organization's cyber risk exposure in real time. In a rapidly evolving, perimeter-less world Armis ensures that organizations continuously see, protect and manage all critical assets. Armis secures Fortune 100, 200 and 500 companies as well as national governments, state and local entities to help keep critical infrastructure, economies and society stay safe and secure 24/7. Armis is a privately held company headquartered in California.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20231212672034/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Westinghouse Celebrates Record-breaking 80 Years of Nuclear Fuel Manufacture at Springfields30.3.2026 14:00:00 CEST | Press release
Fuel manufactured at Springfields has generated enough energy to supply the UK’s electricity demand for 26 years, avoiding the emission of nearly 3 billion tonnes of CO2 The Westinghouse Springfields facility in Lancashire, UK, has marked a significant milestone as the oldest continuous nuclear fuel manufacturing site in the world, starting from its original license on the 28th, March 1946. The site was chosen by the UK Government to develop nuclear fuel for the world’s earliest civil nuclear power stations, as well as subsequent Magnox and Advanced Gas Reactors (AGR) reactors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330135973/en/ From left to right: Sophie Lemaire; Marc Chevrel; Rory O'Neill; Craig Boothby; and Robert Gofton, CEO at Nuclear Institute Across the last eight decades, the Springfields site has supported the UK nuclear fleet, manufacturing more than eight million AGR pins, sintering and pressing over 5
HistoSonics Treats First Patients Evaluating the Edison® Histotripsy System for the Treatment of Benign Prostatic Hyperplasia (BPH)30.3.2026 14:00:00 CEST | Press release
HistoSonics, the developer of the Edison® Histotripsy System and novel histotripsy therapy platform, today announced the successful treatments of the first patients in WOLVERINE, a prospective feasibility trial evaluating the Edison® Histotripsy System for the treatment of benign prostatic hyperplasia (BPH) at Prince of Wales Hospital in Hong Kong, a teaching hospital for The Chinese University of Hong Kong. The Edison System is a novel, non-invasive, image guided platform that uses the mechanical properties of focused ultrasound, called histotripsy, to destroy unwanted tissue without the need for invasive procedures, and with potentially fewer side effects than traditional, invasive therapies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330349844/en/ HistoSonics Non-Invasive Edison Histotripsy System. Image credit: HistoSonics WOLVERINE is a prospective, multi-center, single-arm feasibility trial designed to evaluate
Biocytogen Grants Taisho Pharmaceutical a License to its RenNano® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 13:00:00 CEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro
Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a
Samsung Biologics Strike: Labor Union Warns of CDMO Supply Chain Risks Following Overwhelming Vote30.3.2026 11:52:00 CEST | Press release
Union members overwhelmingly approve strike action with 95.52% voting in favor on a 95.38% turnout, clearing the final legal hurdle after mediation ceased.Union emphasizes this is a fight against structural corporate governance issues, citing unresolved allegations concerning unfair labor practices and ESG compliance risks.Management adhered to a group-level wage guideline rather than bargaining on the basis of Samsung Biologics' own performance, exposing a lack of independent bargaining authority. The Samsung Biologics Labor Union (President: Jaesung Park), representing approximately 75% of the company's total employees, announced today that its members have overwhelmingly voted in favor of a strike, with 95.52% voting in favor on a 95.38% turnout during a voting period from March 24 to March 29. Following the Incheon Regional Labor Relations Commission's decision to cease mediation, the union has now secured the legal mandate to strike. The union stressed that this strike is not mere
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
